Literature DB >> 20027027

Inherited thrombophilia polymorphisms and pregnancy outcomes in nulliparous women.

Joanne M Said1, John R Higgins, Eric K Moses, Susan P Walker, Anthony J Borg, Paul T Monagle, Shaun P Brennecke.   

Abstract

OBJECTIVE: To estimate the association between five commonly inherited thrombophilia polymorphisms and adverse pregnancy outcomes in women who had no prior history of adverse pregnancy outcomes or personal or family history of venous thromboembolism.
METHODS: Healthy nulliparous women (n=2,034) were recruited to this prospective cohort study before 22 weeks of gestation. Genotyping for factor V Leiden, prothrombin gene mutation, methylenetetrahydrofolate reductase enzyme (MTHFR) C677T, MTHFR A1298C, and thrombomodulin polymorphism was performed. Clinicians caring for women were blinded to the results of thrombophilia tests. The primary composite outcome was the development of severe preeclampsia, fetal growth restriction, placental abruption, stillbirth, or neonatal death.
RESULTS: Complete molecular results and pregnancy outcome data were available in 1,707 women. These complications were experienced by 136 women (8.0%). Multivariable logistic regression demonstrated two statistically significant findings. Women who carried the prothrombin gene mutation had an odds ratio of 3.58 (95% confidence interval [CI] 1.20-10.61, P=.02) for the development of the composite primary outcome. Homozygous carriers of the MTHFR 1298 polymorphism had an odds ratio of 0.26 (95% CI 0.08-0.86, P=.03). None of the other polymorphisms studied showed a significant association with the development of the primary outcome in this cohort of women.
CONCLUSION: Prothrombin gene mutation confers an increased risk for the development of adverse pregnancy outcomes in otherwise asymptomatic, nulliparous women, whereas homozygosity for MTHFR 1298 may protect against these complications. The majority of asymptomatic women who carry an inherited thrombophilia polymorphism have a successful pregnancy outcome. LEVEL OF EVIDENCE: II.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20027027     DOI: 10.1097/AOG.0b013e3181c68907

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  16 in total

Review 1.  Novel insights into molecular mechanisms of abruption-induced preterm birth.

Authors:  Catalin S Buhimschi; Frederik Schatz; Graciela Krikun; Irina A Buhimschi; Charles J Lockwood
Journal:  Expert Rev Mol Med       Date:  2010-11-01       Impact factor: 5.600

2.  Free protein s reference ranges in gravidas without hereditary and acquired thrombophilia.

Authors:  Ahmet Basaran; Özgür Deren; Yahya Buyukasik; Mustafa Basaran
Journal:  Indian J Hematol Blood Transfus       Date:  2014-08-17       Impact factor: 0.900

3.  FIGO (international Federation of Gynecology and obstetrics) initiative on fetal growth: best practice advice for screening, diagnosis, and management of fetal growth restriction.

Authors:  Nir Melamed; Ahmet Baschat; Yoav Yinon; Apostolos Athanasiadis; Federico Mecacci; Francesc Figueras; Vincenzo Berghella; Amala Nazareth; Muna Tahlak; H David McIntyre; Fabrício Da Silva Costa; Anne B Kihara; Eran Hadar; Fionnuala McAuliffe; Mark Hanson; Ronald C Ma; Rachel Gooden; Eyal Sheiner; Anil Kapur; Hema Divakar; Diogo Ayres-de-Campos; Liran Hiersch; Liona C Poon; John Kingdom; Roberto Romero; Moshe Hod
Journal:  Int J Gynaecol Obstet       Date:  2021-03       Impact factor: 3.561

4.  Inherited thrombophilia in pregnant women with intrauterine growth restriction.

Authors:  Letitia Coriu; Elena Copaciu; Dan Tulbure; Rodica Talmaci; Diana Secara; Daniel Coriu; Monica Cirstoiu
Journal:  Maedica (Buchar)       Date:  2014-12

Review 5.  The association of factor V leiden and prothrombin gene mutation and placenta-mediated pregnancy complications: a systematic review and meta-analysis of prospective cohort studies.

Authors:  Marc A Rodger; Marisol T Betancourt; Peter Clark; Pelle G Lindqvist; Donna Dizon-Townson; Joanne Said; Uri Seligsohn; Marc Carrier; Ophira Salomon; Ian A Greer
Journal:  PLoS Med       Date:  2010-06-15       Impact factor: 11.069

Review 6.  Thrombophilia and Recurrent Pregnancy Loss: Is heparin still the drug of choice?

Authors:  Adel Abu-Heija
Journal:  Sultan Qaboos Univ Med J       Date:  2014-01-27

Review 7.  The role of proteoglycans in contributing to placental thrombosis and fetal growth restriction.

Authors:  Joanne M Said
Journal:  J Pregnancy       Date:  2011-03-03

8.  Pregnancy complications in G20210A mutation carriers associated with high prothrombin activity.

Authors:  M G Nikolaeva; A P Momot; M S Zainulina; N N Yasafova; I A Taranenko
Journal:  Thromb J       Date:  2021-06-05

9.  Individual risk assessment of adverse pregnancy outcome by multivariate regression analysis may serve as basis for drug intervention studies: retrospective analysis of 426 high-risk patients including ethical aspects.

Authors:  Rolf Becker; Thomas Keller; Holger Kiesewetter; Heiner Fangerau; Uta Bittner
Journal:  Arch Gynecol Obstet       Date:  2013-02-07       Impact factor: 2.344

10.  Prevalence of Factor V Leiden G1691A and Prothrombin G20210A Gene Mutation Among Pregnant Women: Experience from a Multi-Center Study in Nigeria.

Authors:  Sarah O John-Olabode; Kehinde S Okunade; Ayorinde James; Gbenga Olorunfemi; Obiefuna I Ajie; Akinniyi A Osuntoki; Alani S Akanmu
Journal:  J Blood Med       Date:  2021-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.